Largest Segment Driving Growth Of U.S. Nasal Spray Market
The global U.S. Nasal Spray Market is estimated to be valued at US$ 9903.35 Mn or Mn in 2023 and is expected to exhibit a CAGR of 6.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
SWOT Analysis:
· Strength: Wide range of product offerings with innovative formulations and delivery systems
· Weakness: Potential side effects associated with long term use of nasal sprays
· Opportunity: Expanding respiratory disorders patient pool and shift towards over-the-counter medications
· Threats: Intense competition from generic drug manufacturers and alternative treatment options
Key Takeaways:
The U.S. Nasal Spray Market Size was valued at US$ 9903.35 Mn in 2023 and is expected to reach over US$ 16,598.74 Mn by 2030, expanding at a CAGR of 6.8% during the forecast period. Surging cases of allergies among the American population coupled with high adoption of nasal sprays as a convenient treatment option for immediate relief of nasal congestion is anticipated to drive the market.
Regional analysis: The Western and Midwestern regions collectively account for over 60% of the overall U.S market due to high prevalence of indoor & outdoor allergens and damp weather conditions. California represents the fastest growing market, expanding at a CAGR of around 8% between 2023-2030.
Key players operating in the U.S. Nasal Spray Market are GlaxoSmithKline plc, Sanofi S.A., Bayer AG, Merck & Co., Inc., Novartis AG, Johnson & Johnson Services, Inc., Pfizer Inc., Procter & Gamble, AstraZeneca Plc., NeilMed Pharmaceuticals Inc., Church & Dwight Co., Inc., and Neurelis, Inc. GlaxoSmithKline and Sanofi collectively hold over 35% of the market share.
Read More - https://shortkro.com/openup-the-new-avenue-for-the-u-s-nasal-spray-market/
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian